Keywords: Orphan drugs, Designation, Pricing, Funding, Japan, South Korea, Taiwan, Singapore, Australia

Orphan drugs in Asia-Pacific: From designation to pricing, funding and market access

Article | 08 February 2010

Print This

It is estimated that 6%-10% of the world’s population will suffer from a rare disease at one point in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in